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25(OH)D levelsAbstract Background: The most important pathogenic mechanisms involved in the development
of chronic obstructive pulmonary disease (COPD) are protease–antiprotease imbalance, inﬂamma-
tion, lung remodeling and oxidative stress. Interestingly, lower vitamin D levels have been related to
regulation of each of these processes, that is, higher expression of proteases, modulation of inﬂam-
mation, modulation of extracellular matrix turnover, and increased oxidative stress. Thus, one can
speculate that lower vitamin D levels may be linked to increased risk of developing COPD. In some
clinical studies, lower levels of vitamin D, measured as plasma 25-hydroxyvitamin D (25(OH)D),
have been associated with lower lung function and faster lung function decline, but the results
are conﬂicting.
Aim of the study: The aim of this study is to evaluate the evidence of the effect of vitamin D on
COPD.
Subjects and methods: The present study, included 120 subjects, 80 patients diagnosed as COPD
and 40 healthy volunteers (20 smokers and 20 nonsmokers). Plasma 25-OHD was measured
by Enzyme Linked Immunosorbent Assay (DiaSorin, Stillwater, Minnesota, USA) in all study
participants.
Results: The mean concentration of 25-OH-D was signiﬁcantly higher in the reference groups
(smokers and nonsmokers) compared with severe COPD group (p= 0.001, 0.001) respectively.
The mean concentration of 25-OH-D was signiﬁcantly higher in the reference groups (smokers
and nonsmokers) compared with moderate COPD group (p= 0.029, 0.049) respectively.
The mean concentration of 25-OH-D was not signiﬁcantly higher in the reference groups (smok-
ers and nonsmokers) compared with the mild COPD group.rculosis.
806 A.H. Ghoneim et al.Conclusion: We observed a novel association of lower plasma 25(OH)D levels with a higher risk
of COPD.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
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Vitamin D refers to a group of fat-soluble secosteroids respon-
sible for enhancing intestinal absorption of calcium, iron, mag-
nesium, phosphate and zinc. In humans, the most important
compounds in this group are vitamin D3 (also known as chole-
calciferol) and vitamin D2 (ergocalciferol) .Cholecalciferol and
ergocalciferol can be ingested from the diet and from supple-
ments .The body can also synthesize vitamin D (speciﬁcally
cholecalciferol) in the skin, from cholesterol, when sun expo-
sure is adequate (hence its nickname, the ‘‘sunshine vitamin’’).
Synthesis from exposure to sunlight and intake from the diet
generally contributes to the maintenance of adequate serum
concentrations [1].
Vitamin D controls calcium absorption in the small intes-
tine and works with parathyroid hormone to mediate skeletal
mineralization and maintain calcium homeostasis in the blood
stream. In addition, recent epidemiologic studies have
observed relationships between low vitamin D levels and mul-
tiple disease states, probably caused by its anti-inﬂammatory
and immune-modulating properties and possible effects on
cytokine levels [2].Vitamin D and COPD
Chronic obstructive pulmonary disease (COPD) has several
systemic symptoms and consequences .Malnutrition, muscle
weakness and osteoporosis are common comorbidities [3] in
COPD that can be linked to vitamin D deﬁciency. Treatment
with calcium and vitamin D supplementation reduces not only
the risk of osteoporotic fractures [4], but interestingly also
increases muscle strength and prevents falls [5].
This effect is mainly thought to be mediated by vitamin
D. Vitamin D status is most commonly evaluated by measur-
ing 25-hydroxyvitamin D (25-OH-D) instead of the active
1,25-dihydroxy vitamin D. The mechanism by which vitamin
D affects the pathogenesis of COPD is unclear.
Comorbidities of COPD such as reduced bone mineral den-
sity and skeletal muscle weakness have been associated with
low vitamin D serum concentrations [3]. However, studies
show that vitamin D can modulate the activity of various
immune cells which inhibit inﬂammatory responses and regu-
late airway smooth muscles [6]. A review of molecular and
animal experiments showed that vitamin D regulates airway
contraction, inﬂammation, and remodeling in airway smooth
muscles characteristic of COPD [6]. A cross-sectional study
found that higher plasma levels of vitamin D are associated
with increased bone mineral density and exercise capacity
in people with COPD [7].
Evidence also showed that a high dose of vitamin D supple-
mentation improved respiratory muscle strength and exercise
capacity in people with COPD [7]. A study among 414 smokers
with COPD showed that vitamin D deﬁciency is highlyprevalent in this population, and correlates with disease sever-
ity. The study also found that genetic determinants for low
vitamin D levels were associated with an increased risk of
COPD [8].
The relatively long half-life of 25-OH-D makes it a better
marker for both dietary intake and skin synthesis from sun
exposure. The National Health and Nutrition Examination
Survey (NHANES) III study showed a positive correlation
between serum 25-OH-D levels and spirometry performance
[9]. A subsequent study conducted in the UK on a small group
of patients with COPD did not reach the same conclusion.
However, it was found that a higher dietary intake of vitamin
D was associated with better lung function and a lower preva-
lence of COPD [10]. Another study from Belgium showed that
COPD patients often have vitamin D deﬁciency and a low
serum level of vitamin D correlates with the severity of the
disease [8].
The latest consensus suggests levels below 25 nmol/L
indicate deﬁciency, between 25 mol/L and 50 mol/L indicate
insufﬁciency, between 50 nmol/L and 75 nmol/L indicate
satisfactory levels and above 75 nmol/L indicate optimal
levels [11].
Materials and methods
Patients and controls
The COPD group consisted of 80 adults, who were diagnosed
as COPD at the Chest Department, Zagazig University,
Faculty of Medicine, Egypt. The diagnosis was based on the
signs and symptoms, as well as on the results of pulmonary
function tests including: forced expiratory volume by the end
of the ﬁrst second (FEV1) percentage of predicted value
(FEV1/predicted FEV1%) using portable vitalograph copd-6
model 4000 (Vitalograph Ltd, Gort Road business Park,
Ennis, Co. Clare, Ireland) (Fig. 1).
Classiﬁcation of the disease severity (mild, moderate or sev-
ere) was done according to [12] as follows depending upon the
obtained value of FEV1/predicted FEV1%:
 Mild: 80% or above (symptoms should be present to diag-
nose COPD in people with mild airﬂow obstruction).
 Moderate: 50–79%.
 Severe: 30–49%.
 Very severe: below 30% (less than 50% but with respiratory
failure).Very severe cases were excluded from this study.
Classiﬁcation of the severity of cigarette smokers was done
according to the number of pack-years (P-Y): number of cigar-
ettes smoked per day multiplied by the duration in years
(Smoking Index) and divided by 20 as follows [13]:
 Mild smokers: less than 20 P-Y.
 Moderate smokers: 20–49 P-Y.
Table 1 Clinical characteristics of the COPD patients.
Character Mean ± SD
Age 54.9 ± 9
Sex (M/F) 27/7
Cigarette (pack-years) 46.4 ± 1.7
FEV1 (%) 59 ± 3.7
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Note: (1 pack has 20 cigarettes).
Healthy controls (smokers and nonsmokers) collected
from non-chesty patients referred from Outpatient Clinics
and inpatients of different Departments of Zagazig
University Hospitals to the Chest Outpatient Clinic for
clinical and functional assessment e.g. before abdominal,
eye operations etc. and also from voluntary people who work
in this hospital.
All control cases had no historical, clinical or radiological
data suggestive of chest problems and they had normal spiro-
metric data and even smokers and their pulmonary function
tests showed an FEV1/FVC ratio >70%.
Determination of vitamin D
Plasma 25-OHD was measured by Enzyme Linked
Immunosorbent Assay (DiaSorin, Stillwater, Minnesota,
USA) in all study participants, as previously described.
Method description
The IDS 25-Hydroxy vitamin D EIA kit is an enzyme
immunoassay for the quantitation of 25-OH D and other
hydroxylated metabolites in serum or plasma. Calibrators,
controls and samples are diluted with biotin labeled 25-OH
D. The diluted samples are incubated in microtitre wells which
are coated with a highly speciﬁc sheep 25-OH D antibody for
2 h at room temperature before aspiration and washing.
Enzyme (horseradish peroxidase) labeled avidin, is added
and binds selectively to complexed biotin and, following a fur-
ther wash step, color is developed using a chromogenic sub-
strate (TMB). The absorbance of the stopped reaction
mixtures are read in a microtitre plate reader, color intensity
developed being inversely proportional to the concentration
of 25-OH D [14].
Specimen collection and storage
The assay should be performed using serum or plasma
(EDTA or heparin) specimens. Specimens should be
separated as soon as possible after collection. For long term
storage, it is stored at 20 C. Avoided repeated freeze/thaw
of samples.Figure 1 A portable vitalograph copd-6.Quality control
The regular use of control samples at several analyzed levels is
advised to ensure day-to-day validity of results. Two kit con-
trols are provided. The controls should be tested as unknowns.
Quality Control charts should be maintained to follow the
assay performance.
Expected values
The following range has been determined using the IDS
25-Hydroxy vitamin D EIA kit and is provided for guidance
only. Each laboratory should determine ranges for their local
population.
Normal adults: 47.7–144 nmol/L (n= 36).
Statistical analyses
All statistical analyses were carried out using the SPSS (statis-
tical package for the social science software) statistical package
version 20.0 (SPSS Inc., Chicago, IL, USA) for Windows.
Quantitative data were expressed as mean and standard devia-
tion (X + SD) and analyzed by applying student t-test for
comparison of two groups of normally distributed variables.
The results of the ‘‘t’’-value are then checked on student’s
‘‘t’’-table to ﬁnd out the signiﬁcance level (p-value) according
to the degree of freedom. All these tests were used as tests of
signiﬁcance at P< 0.05. [15].
Results
A total of 120 subjects, including 80 COPD patients, 20
healthy smokers and 20 nonsmokers as control subjects were
studied. The mean age of the COPD patients was (54.9 ± 9),
male/female ratio was (27/7), number of pack-years wasTable 2 Clinical characteristics of the smoker control.
Character Mean ± SD
Age 52.2 ± 2.1
Sex (M/F) 20/0
Cigarette (pack-years) 33.7 ± 1.2
Table 3 Clinical characteristics of the nonsmoker control.
Character Mean ± SD
Age 55.7 ± 2.3
Sex (M/F) 11/9
Table 4 25-OH-D levels, in severe COPD patients and reference groups (smokers and nonsmokers) [mean (±SD)].
Groups parameter COPD (severe)
n= 24
Smoker
n= 20
P Nonsmoker
n= 20
P
VD ng/mL 30.7 ± 9.2a,b 53.4 ± 13.3a 0.001 52.5 ± 19.5b 0.001
Range 18–53 39–89 – 22–100 –
a Signiﬁcant COPD patient with smokers.
b Signiﬁcant COPD patients with nonsmokers.
Figure 2 25-OH-D levels, in severe COPD patients and reference groups (smokers and nonsmokers), where (1 = Severe COPD,
2 = Smoker, 3 = nonsmoker).
Table 5 25-OH-D levels, in moderate COPD patients and control groups (smokers and nonsmokers) [mean (±SD)].
Groups parameter COPD (moderate)
n= 40
Smoker
n= 20
P Nonsmoker
n= 20
P
VD ng/mL 44.7 ± 11.1a,b 53.4 ± 13.3a 0.029 52.5 ± 19.5b 0.049
Range 28–71 39–89 – 22–100 –
a Signiﬁcant smokers with COPD patient.
b COPD patients with nonsmokers.
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clinical characteristics of the COPD patients are shown in
Table 1.
Among whole patients, (40) of them were classiﬁed as mod-
erate, (24) as severe and (16) as mild. In healthy smoker and
nonsmoker control groups the mean age was (52.2 ± 2.1)
and (55.7 ± 2.3) respectively, male/female ratio was (20/0)
and (11/9), respectively. Number of pack-years was
(33.7 ± 1.2) in healthy smoker controls. The clinical character-
istics of the healthy smoker and nonsmoker control groups are
shown in Tables 2 and 3.
The mean concentration of 25-OH-D was signiﬁcantly
higher in the reference groups (smokers and nonsmokers)(53.4 ± 13.3), (52.5 ± 19.5) ng/mL, respectively compared
with (30.7 ± 9.2) ng/mL in the severe COPD group
(p= 0.001, 0.001), as shown in Table 4, Fig. 2.
The mean concentration of 25-OH-D was signiﬁcantly
higher in the reference groups (smokers and nonsmokers)
(53.4 ± 13.3), (52.5 ± 19.5) ng/mL, respectively compared
with (44.7 ± 11.1) ng/mL in the moderate COPD group
(P= 0.029, 0.049) respectively, as shown in Table 5, Fig. 3.
The mean concentration of 25-OH-D was not signiﬁcantly
higher in the reference groups (smokers and nonsmokers)
(53.4 ± 13.3), (52.5 ± 19.5) ng/mL, respectively compared
with (48.9 ± 15.4) ng/mL in the mild COPD group, as shown
in Table 6, Fig. 4.
Figure 3 25-OH-D levels, in moderate COPD patients and control groups (smokers and nonsmokers), where (1 = moderate COPD,
2 = Smoker, 3 = nonsmoker).
Table 6 25-OH-D levels, in mild COPD patients and control
groups (smokers and nonsmokers) [mean (±SD)].
Groups
parameter
COPD
(mild)
n= 16
Smoker
n= 20
P Nonsmoker
n= 20
P
VD ng/mL 48.9 ± 15.4 53.4 ± 13.3 NS 52.5 ± 19.5 NS
Range 25–85 39–89 – 22–100 –
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Vitamin D is a seco-steroid hormone important in bone miner-
alization and calcium homeostasis. Recently, research has
found that vitamin D may play a role in multiple chronic dis-
eases such as cancer, autoimmune diseases, infections, and car-
diovascular disorders (see Fig. 5).
Vitamin D may also have a role in several diseases involv-
ing the respiratory system. Higher vitamin D concentrations,
assessed by 25-hydroxyvitamin D [25(OH)D], have been asso-
ciated with better lung function as measured by forced expira-
tory volume in 1s (FEV1) in a large cross-sectional study of the
U.S. Population in the NHANES III. Although the precise
connection between vitamin D status and lung function is
unclear at this point, the mechanism by which vitamin D
improves lung function may be through its action on regulat-
ing inﬂammation, inducing antimicrobial peptides, and/or its
action on muscle. There have been numerous studies looking
at vitamin D status in association with various lung diseases
focusing on asthma, chronic obstructive pulmonary disease
(COPD), cystic ﬁbrosis (CF), and respiratory infections.
These studies have demonstrated a high prevalence of vitamin
D deﬁciency in their participants [16].Our study indicates that the mean concentration of 25-OH-
D was signiﬁcantly higher in the reference groups (smokers
and nonsmokers) (53.4 ± 3.3), (52.5 ± 19.5) ng/mL, respec-
tively compared with (30.7 ± 9.2) ng/mL in the severe
COPD group (p= 0.001).
Also the mean concentration of 25-OH-D was signiﬁcantly
higher in the reference groups (smokers and nonsmokers)
(53.4 ± 13.3), (52.5 ± 19.5) ng/mL, respectively compared
with (44.7 ± 11.1) ng/mL in the moderate COPD group
(p= 0.029, 0.049 respectively).
But the mean concentration of 25-OH-D was not signiﬁ-
cantly higher in the reference groups (smokers and nonsmok-
ers) (53.4 ± 3.3), (52.5 ± 19.5) ng/mL, respectively compared
with (48.9 ± 15.4) ng/mL in the mild COPD group.
We found that there is a correlation between low levels of
vitamin and the severity of the disease; this is consistent with
[8]. A number of studies have shown an association between
vitamin D deﬁciency and severity of COPD [8,17]. Lower vita-
min D status in COPD may be due to diminished production
of pre-vitamin D3 associated with skin aging caused by smok-
ing and limited UVB exposure [18,19].
Studies have shown that the degree of vitamin D deﬁciency
correlates with the severity of the disease as measured by the
reduction of FEV1 [9,8,17].
The connection between Vit.D status and COPD has
attracted attention in the recent years. This is based on data
from observational studies that determined levels of Vit.D in
COPD patients. Black and colleagues examined data from
the NHANES III data set (cross-sectional survey of 14091
adults in the US). After adjustment for potential confounders,
a strong relationship between serum levels of Vit.D and lung
function (FEV1 and FVC) was found [9].
A number of studies have reported on 25-(OH)D3 levels in
COPD patients. [20] found Vit.D deﬁciency (in this study
Figure 4 25-OH-D levels, in mild COPD patients and control groups (smokers and nonsmokers), where (1 = mild COPD, 2 = Smoker,
3 = nonsmoker).
Figure 5 25-OH-D levels, in Severe, Moderate, mild COPD
patients and control groups (smokers and nonsmokers) [mean
(±SD)].
810 A.H. Ghoneim et al.deﬁned as below 20 ng/ml) in more than 50% of a cohort wait-
ing for lung transplantation [20].
A recent study showed that Vit.D deﬁciency is highly preva-
lent in COPD and correlates with variants in the Vit.D binding
gene [8]. There are several factors that could account for Vit.D
deﬁciency in COPD patients: poor diet, a reduced capacity of
aging skin for Vit.D synthesis, reduced outdoor activity and
therefore sun exposure, an increased catabolism by glucocorti-
coids, impaired activation because of renal dysfunction, and a
lower storage capacity in muscles or fat due to wasting [21].
Many steps of the Vit.D pathway (intake, synthesis, storage,
and metabolism) can potentially be disturbed in COPD
patients. A single nucleotide polymorphism (SNP) of the
DBP was shown to be associated with a decreased risk of
COPD by a mechanism that is unclear [22]. Similar SNPs in
the gene coding for DBP may inﬂuence levels of circulating
25-(OH)D3 and 1,25-(OH)2D3 [23,24].
Therefore it has been hypothesized that their protective role
might be mediated by the bioavailability of 1,25-(OH)2D3 [19].The mechanisms that link Vit.D biology with the development
of COPD are largely speculative:
(1) The association of Vit.D deﬁciency and reduced lung
function could depend on the calcemic effects of
Vit.D. The vital capacity and total lung capacity were
found to decline with an increasing number of thoracic
vertebral fractures as a direct consequence of Vit.D deﬁ-
ciency. [25,26] 3030 ambulatory COPD patients were
observed and a strong association between COPD sever-
ity and fractures was found [26]. Kyphosis related to
osteoporosis caused limitation in rib mobility and inspi-
ratory muscle function and correlated with a reduction
in FEV1 and FVC [27]. The altered properties of the
thoracic skeleton could result in failure of the respira-
tory muscles contributing to the pathophysiology of
COPD.
(2) Vit.D deﬁciency could result in altered host defense of
the lung with subsequent growth of an abnormal ﬂora
that triggers inﬂammation. Acute exacerbations of
COPD are an important cause of hospitalization and
lead to a faster decline in FEV1 [28].
Exacerbations are triggered by viruses, bacteria, atypical
strains, or a combination of these [29–31].
Potential bacterial pathogens are detected in about 50%
of exacerbations. A therapeutic consequence would be
the up-regulation of the innate immune defense system.
Wang and colleagues demonstrated that genes
coding for the antimicrobial peptide cathelicidin
(LL-37/hCAP-18) are regulated by VDRE-containing
promoters [32]. In cultured monocytes, a local increase
of the 1,25D3-VDR complex stimulates the production
of LL-37, resulting in an improved intracellular eradica-
tion of Mycobacterium tuberculosis [33].
Association of vitamin D status in chronic obstructive pulmonary disease 811The data demonstrated that the activation of TLRs on
human monocytes triggers a microbicidal pathway that
is dependent on both the endogenous production and
action of 1,25-(OH)2D3 through the VDR.
(3) The effect of Vit.D on extracellular matrix homeostasis
not only in bone tissue, but also within the lung may
have a role in COPD development. Boyan et al. found
Vit.D to be an autocrine regulator of extracellular
matrix turnover and growth factor release via matrix
metalloproteinases [34].
Matrix metalloproteinasis-9 (MMP-9) has been shown
to be elevated in induced sputum of COPD patients
and a causative role has been suggested in the develop-
ment of COPD [35]. Vit.D also to attenuates TNF
alpha induced up regulation of MMP-9 in ker-
atinocytes [36].
Vit.D deﬁciency may lead to a reduced attenuation of
MMP-9 activity resulting in enhanced degradation of
lung parenchyma. Recently, it has been recognized that
COPD is a systemic disease with several closely related
comorbidities [37]. Interestingly, Vit.D deﬁciency is
associated with an equivalent spectrum of diseases
including coronary heart disease, cancer; inﬂammatory
disease and infection [18]. Comorbidities of COPD
such as reduced bone mineral density and skeletal
muscle weakness [5] have been associated with low
Vit.D serum concentrations.
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